Document is current
Any future updates will be listed below
-
Authors
Bhimani, Jenna
Wang, Peng
Gallagher, Grace B.
O’Connell, Kelli
Persaud, Sonia
Blinder, Victoria S.
Burganowski, Rachael
Ergas, Isaac J.
Griggs, Jennifer J.
Heon, Narre
Kolevska, Tatjana
Kotsurovskyy, Yuriy
Kroenke, Candyce H.
Laurent, Cecile A.
Liu, Raymond
Nakata, Kanichi G.
Roh, Janise M.
Tabatabai, Sara
Valice, Emily
Bandera, Elisa V.
Aiello Bowles, Erin J.
Kushi, Lawrence H.
Kantor, Elizabeth D.
-
Funding
Funding for this research was provided by:
National Cancer Institute (R37CA222793)
Geoffrey Beene Cancer Research Center
- License Information
-
More Information
Article History
Received: 2 May 2025
Accepted: 10 June 2025
First Online: 6 July 2025
Declarations
:
: Dr. Wang was former employee of Daiichi Sankyo, Inc (6/2022–4/2023). Dr. Bandera served as member of Pfizer’s Advisory Board to enhance minority participation in clinical trials (7/2021–8/2023). Dr. Liu served as member of Pfizer’s think tank on real-world evidence sponsored by Pfizer on 11/28/23. Dr. Liu’s research funding (institutional) unrelated to this current work: Genentech, AstraZeneca, Bristol Myers Squibb, Exact Sciences, Biotheranostics, and Beigene. Other authors have no COI to declare.
: IRB approval was obtained from Memorial Sloan Kettering Cancer Center, Rutgers University, KPNC, and KPWA with a waiver of informed consent to extract and analyze patient data at KPNC and KPWA.
